中枢神经系统特发炎性脱髓鞘疾病体液生物标志物临床应用进展

Progress in clinical application of humoral biomarkers for central nervous system inflammatory demyelinating diseases

中枢神经系统特发炎性脱髓鞘疾病(CNS-IIDD)是一类炎性脱髓鞘自身免疫系统疾病,其病程主要为反复发作及缓解,部分呈现持续进展,患者常因此出现残疾。近几年该类疾病呈现逐年增长趋势,给患者家庭及社会带来巨大负担。通过体液生物标志物识别CNS-IIDD,并寻找能可靠预测疾病发作及进展的生物标志物,以此筛选出具有高致残风险的人群进行预防性治疗,是控制疾病发作和进展,同时缓解患者生存和经济压力最有效的策略之一。本文对CNS-IIDD体液生物标志物识别及预测疾病活动与进展的研究进展进行综述,旨在为CNS-IIDD发作的预防及控制提供新的思路。

Central nervous system idiopathic inflammatory demyelinating diseases(CNS-IIDD)is an autoimmune disorder characterized by inflammatory demyelination.The disease follows a course of recurrent attacks and remission,with some cases displaying continuous progression,often resulting in disability.The incidence of CNS-IIDD has been increasing,imposing a substantial burden on both patients′families and society in recent years.A promising strategy for disease management involves the identification of humoral biomarkers to diagnose CNS-IIDD and predict disease attack and progression.Such biomarkers could aid in identifying individuals at high risk of disability,enabling targeted preventive interventions.This study summarizes advancements in the identification of humoral biomarkers and their potential for predicting disease activity and progression to offer novel insights into the management of CNS-IIDD.